BioNTech SE Sponsored ADR (NASDAQ:BNTX) Short Interest Down 20.7% in March

BioNTech SE Sponsored ADR (NASDAQ:BNTX) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,537,489 shares, a decrease of 20.7% from the February 26th total of 4,462,537 shares. Based on an average daily volume of 2,504,103 shares, the short-interest ratio is presently 1.4 days. Approximately 1.8% of the company’s shares are sold short.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC lifted its stake in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the last quarter. EFG International AG acquired a new position in BioNTech in the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd grew its stake in BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the last quarter. Financial Consulate Inc. bought a new position in BioNTech in the 3rd quarter worth $36,000. Finally, Huntington National Bank raised its holdings in BioNTech by 1,266.7% in the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $85.68 on Friday. The stock has a market capitalization of $20.56 billion, a P/E ratio of -16.35 and a beta of 1.51. The business has a 50-day moving average of $103.70 and a two-hundred day moving average of $101.60. BioNTech has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research note on Wednesday, March 11th. Citigroup dropped their target price on shares of BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a report on Wednesday. Leerink Partners downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a research report on Monday, February 2nd. Finally, Bank of America reaffirmed a “buy” rating and issued a $128.00 target price on shares of BioNTech in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.